| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 03/01/2007 | US20070049580 Anxiolytic agents with reduced sedative and ataxic effects |
| 03/01/2007 | US20070049558 New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors |
| 03/01/2007 | US20070049535 Preventive/remedy for diabetic complications using oligopeptide |
| 03/01/2007 | US20070048846 Detecting ligands that stimulate the proliferation and/or development of hematopoietic, lymphoid and myeloid cells |
| 03/01/2007 | US20070048804 Methods of detecting cytokine receptor zcytor19 ligand |
| 03/01/2007 | US20070048799 hematopoietic cytokine receptor polypeptide encoded by nucleotides equences for use in the treatment of cancer; restoring normal blood cell levels in patients suffering from anemia, thrombocytopenia, and neutropenia or receiving chemotherapy for cancer; biodrugs |
| 03/01/2007 | US20070048772 for inhibiting apoptosis in mammalian cells; zinc finger domains; consensus sequences; genetic engineering; for treating AIDS, alzheimer's disease, parkinson's disease, amyotrophic lateral sclerosis (ALS), retinitis pigmentosa, autoimmune diseases |
| 03/01/2007 | US20070048319 Antibodies that bind both bcma and taci |
| 03/01/2007 | US20070048287 Molecular antigen array |
| 03/01/2007 | US20070048286 Method of treating dopaminergic and GABA-nergic disorders |
| 03/01/2007 | US20070048255 Method for treatment of demyelinating central nervous system disease |
| 03/01/2007 | US20070048221 Antibodies that bind both bcma and taci |
| 03/01/2007 | US20070048220 Antibodies that bind both bcma and taci |
| 03/01/2007 | US20070044795 Method and apparatus for dispensing inhalator medicament |
| 03/01/2007 | CA2621158A1 N-oxides as prodrugs of piperazine & piperidine derivatives |
| 03/01/2007 | CA2620418A1 Benztropine compounds and uses thereof |
| 03/01/2007 | CA2620364A1 Methods for treatment of headaches by administration of oxytocin |
| 03/01/2007 | CA2620333A1 Neurogenesis by muscarinic receptor modulation |
| 03/01/2007 | CA2620257A1 P38 map kinase inhibitors and methods for using the same |
| 03/01/2007 | CA2620202A1 Therapy procedure for drug delivery for trigeminal pain |
| 03/01/2007 | CA2620032A1 Polymer conjugates of k-252a and derivatives thereof |
| 03/01/2007 | CA2620024A1 Compositions and methods for improving functional vascular integrity, cellular survival and reducing apoptosis in ischemia or after ischemic episode in the brain |
| 03/01/2007 | CA2619972A1 Pyrrolopyridine, pyrrolopyrimidine and pyrazolopyridine compounds, compositions comprising them, and methods of their use |
| 03/01/2007 | CA2619770A1 Phenylpyridone derivative |
| 03/01/2007 | CA2619481A1 Methods for the treatment of anxiety and for identification of anxiolytic agents |
| 03/01/2007 | CA2619362A1 Fused tricyclic mglur1 antagonists as therapeutic agents |
| 03/01/2007 | CA2619052A1 Anti-il-23 antibiodies |
| 03/01/2007 | CA2618700A1 Heteroaryl-substituted diazatricycloalkanes, methods for its preparation and use thereof |
| 03/01/2007 | CA2617975A1 Combination of a hypnotic agent and r(+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenl)ethyl]-4-piperidinemethanol and therapeutic application thereof |
| 03/01/2007 | CA2611736A1 Benzo[b]furane and benzo[b]thiophene derivatives |
| 02/28/2007 | EP1757689A2 Mammalian apoptosis inhibitor protein gene family, primers, probes and detection methods |
| 02/28/2007 | EP1757617A1 Ret Ligand (RetL) for stimulating neural and renal growth |
| 02/28/2007 | EP1757616A2 Semaphorin receptors |
| 02/28/2007 | EP1757608A1 New benzazepine derivatives, medicaments containing the same and their use in the preparation of medicaments |
| 02/28/2007 | EP1757605A1 Cyclic amine compound |
| 02/28/2007 | EP1757602A1 Vla-4 inhibitor |
| 02/28/2007 | EP1757600A2 Treatment of affective disorders by the combined action of a nicotinic receptor agonist and a monoaminergic substance |
| 02/28/2007 | EP1757594A1 Quinazoline derivative |
| 02/28/2007 | EP1757591A1 Cinnamide compound |
| 02/28/2007 | EP1757587A1 Substituted pyrazoline compounds, their preparation and use as medicaments |
| 02/28/2007 | EP1757586A1 Polysbustituirte 1,1-pyridinylaminocyclopropanamin derivate, verfahren zu deren herstellung und diese enthaltende pharmatuetische zusammensetzung |
| 02/28/2007 | EP1757584A1 Heterocyclic substituted amides, their production and their use |
| 02/28/2007 | EP1757325A1 Use of botulinum toxin for treating myofascial pain |
| 02/28/2007 | EP1757321A2 Methods and apparatus for relieving headaches, rhinitis and other common ailments |
| 02/28/2007 | EP1757292A1 Method of treating ocd and tic disorders |
| 02/28/2007 | EP1757291A2 Stabilized formulations of 6-hydroxy-3-(4-[2-(piperidin-1-YL)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene and salts thereof |
| 02/28/2007 | EP1757289A1 Composition for acceleration of alcohol metabolism or recuperation from fatigue through gluconeogenesis |
| 02/28/2007 | EP1757286A1 The application of l-n-butylphthlide in preventing and treating dementia |
| 02/28/2007 | EP1757280A1 Transdermal patch for administering sufentanyl |
| 02/28/2007 | EP1756111A1 Alkyl substituted indoloquinoxalines |
| 02/28/2007 | EP1756105A1 Substituted imidazo[1,2-a]pyridine compounds and drugs containing substituted imidazo[1,2-a]pyridine compounds |
| 02/28/2007 | EP1756104A1 Tetrahydronaphthyridine derivatives useful as histamine h3 receptor ligands |
| 02/28/2007 | EP1756094A1 3-cycloalkylbenzazepines as histamine h3 antagonists |
| 02/28/2007 | EP1756092A1 Novel inhibitors of rho-kinases |
| 02/28/2007 | EP1756087A1 Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase |
| 02/28/2007 | EP1756086A1 Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists |
| 02/28/2007 | EP1756083A1 3-arylsulfonyl-quinolines as 5-ht6 receptor antagonists for the treatment of cns disorders |
| 02/28/2007 | EP1756071A1 Benzoxazolone derivatives, processes for preparing them and their uses |
| 02/28/2007 | EP1756070A2 Crystalline forms of n-desmethylclozapine |
| 02/28/2007 | EP1756066A1 Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high cb1/cb2 receptor subtype selectivity |
| 02/28/2007 | EP1756061A1 Therapeutic compounds: pyridine n oxide scaffold |
| 02/28/2007 | EP1756051A1 Histamine h3 receptor agents, preparation and therapeutic uses |
| 02/28/2007 | EP1756050A1 Aminomethyl-azacycle derivatives as inhibitors of monoamine uptake |
| 02/28/2007 | EP1755743A2 Triglycerides, fatty acids, alcohols as cns modulators |
| 02/28/2007 | EP1755678A2 Active substance combination of a carbinol compound and an opioid |
| 02/28/2007 | EP1755654A2 Methods and systems for treatment of neurological diseases of the central nervous system |
| 02/28/2007 | EP1755647A1 Treatment of amyotrophic lateral sclerosis |
| 02/28/2007 | EP1755614A1 Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome |
| 02/28/2007 | EP1755604A2 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |
| 02/28/2007 | EP1755602A1 Monoamine neurotransmitter re-uptake inhibitor for the inhibition of beta-amyloid (a beta 40 and a beta 42) generation |
| 02/28/2007 | EP1755583A1 Use of neboglamine (cr 2249) as an antipsychotic and neuroprotective |
| 02/28/2007 | EP1755565A2 Soft gelatin capsule comprising omega-3 polyunsaturated fatty acid |
| 02/28/2007 | EP1755393A2 Methods of diminishing co-abuse potential |
| 02/28/2007 | EP1691892B1 Tamper resistant co-extruded dosage form containing an active agent and an adverse agent and process of making same |
| 02/28/2007 | EP1651223B1 2-methoxymethyl-3-(3,4-dichlorophenyl)-8-azabicyclo[3.2.1]octane tartrate salts |
| 02/28/2007 | EP1581538B1 Tetracyclic 3-substituted indoles having serotonin receptor affinity |
| 02/28/2007 | EP1572179B1 Pharmaceutical composition comprising a ltb4 antagonist and a cox-2 inhibitor or a combined cox1/2 inhibitor |
| 02/28/2007 | EP1509522B1 1-(aminoalkyl)-3-sulfonylazaindoles as 5-hydroxytryptamine-6 ligands |
| 02/28/2007 | EP1507776B1 2-oxo-1,3,4-trihydroquinazolinyl derivatives for the treatment of cell proliferation-related disorders |
| 02/28/2007 | EP1492771B1 Quinoline and isoquinoline derivatives, method for the production thereof and use thereof as anti-inflammatory agents |
| 02/28/2007 | EP1482951B8 1-alpha-hydroxy-2-methylene-19-nor-pregnacalciferol and its uses |
| 02/28/2007 | EP1465893B1 Derivatives of 5-(pyridin-3-yl)-1-azabicyclo (3.2.1) octane, the preparation thereof and the application of same in therapeutics |
| 02/28/2007 | EP1458703B1 Isochroman compounds for treatment of cns disorders |
| 02/28/2007 | EP1456209B1 A2a adenosine receptor antagonists |
| 02/28/2007 | EP1425286B1 Substituted 7-aza-[2.2.1]bicycloheptanes for the treatment of diseases |
| 02/28/2007 | EP1418912B1 Isoxazolopyridinones |
| 02/28/2007 | EP1370531B1 Phenylalanine enamide derivatives possessing a cyclobutene group, for use as integrin inhibitors |
| 02/28/2007 | EP1368094B1 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo- 1,5-a|-1,3,5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands |
| 02/28/2007 | EP1346041B1 Therapeutic agents and methods of use thereof for treating an amyloidogenic disease |
| 02/28/2007 | EP1343561B1 Serine protease inhibitors |
| 02/28/2007 | EP1265606B9 Cell adhesion inhibitors |
| 02/28/2007 | EP1204679B1 Peptides containing n-substituted d-amino acids for preventing beta-strand association |
| 02/28/2007 | EP1102753B1 Pyrazoles as estrogen receptor modulators |
| 02/28/2007 | EP1096926B1 Methods and compounds for treating depression |
| 02/28/2007 | EP1033979B9 Combination of cyp2a enzyme inhibitors and nicotine and their therapeutic use |
| 02/28/2007 | EP1025077B1 Novel aryloxy-alkyl-dialkylamines |
| 02/28/2007 | EP0799034B1 Use of aromatic or branched chain amino acids for the treatment of movement disorders |
| 02/28/2007 | EP0726948B1 Method of inducing and maintaining neuronal cells |
| 02/28/2007 | CN1922320A Antisense compounds targeted to connexins and methods of use thereof |
| 02/28/2007 | CN1922209A Anti-ab antibody |